RBC Capital initiated coverage of BeiGene (ONC) with an Outperform rating and $312 price target RBC sees a path to robust revenue growth ...

BeiGene (ONC) announced the discontinuation of its clinical development program for ociperlimab (BGB-A1217), an anti-TIGIT antibody, as a ...

“ONC is one of those organizations that was created and is now there forever, far past its initial use,” said Brian J. Miller, a nonresident fellow at the American Enterprise ...